Novel flavonoid hybrids as potent antiviral agents against hepatitis A: Design, synthesis and biological evaluation

Eur J Med Chem. 2022 May 14;238:114452. doi: 10.1016/j.ejmech.2022.114452. Online ahead of print.ABSTRACTTwo series of flavonoid hybrids, totaling 42 compounds, were designed, synthesized and evaluated to develop antiviral compounds effective against hepatitis A virus (HAV). A recombinant viral screening system revealed that most of the synthesized derivatives exhibited significant anti-HAV activity, and compounds B2, B3, B5 and B27 were identified as potential inhibitors of HAV. Post-treatment of cells with B2, B3, B5 and B27 after HAV infection strongly suppressed HAV infection, whereas pretreatment or simultaneous treatment were ineffective. Furthermore, these four compounds significantly inhibited HAV (HM175/18f strain) production in a dose-dependent manner. Analyses using HAV subgenomic replicon systems indicated that these compounds specifically inhibit HAV RNA replication. More importantly, the most potent compounds B2 and B27 also showed clear inhibitory effects on two other HAV strains, KRM031 and TKM005, which also isolated from clinical patients. Our study is the first to report these newly designed flavonoid hybrids as lead compounds for the development of novel anti-HAV drugs.PMID:35597006 | DOI:10.1016/j.ejmech.2022.114452
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Source Type: research